Afficher la notice abrégée

Self-application of aminoglycoside-based creams to treat cutaneous leishmaniasis in travelers

dc.rights.licenseopenen_US
hal.structure.identifierCHU Pitié-Salpêtrière [AP-HP]
dc.contributor.authorMOURI, Oussama
hal.structure.identifierHôpital Necker - Enfants Malades [AP-HP]
dc.contributor.authorMELENOTTE, Clea
hal.structure.identifierHôpital privé du Confluent [Nantes]
dc.contributor.authorGUERY, Romain
hal.structure.identifierHôpital Necker - Enfants Malades [AP-HP]
dc.contributor.authorCOTTERET, Camille
hal.structure.identifierHôpital Necker - Enfants Malades [AP-HP]
dc.contributor.authorSCHWEITZER-CHAPUT, Arnaud
hal.structure.identifierCHU Pitié-Salpêtrière [AP-HP]
dc.contributor.authorPÉRIGNON, Alice
hal.structure.identifierCHU Pitié-Salpêtrière [AP-HP]
dc.contributor.authorTHELLIER, Marc
hal.structure.identifierCentre d'Investigation Clinique 1426 [CIC 1426]
dc.contributor.authorBOURRAT, Emmanuelle
hal.structure.identifierCentre d'Investigation Clinique 1426 [CIC 1426]
dc.contributor.authorKAGUELIDOU, Florentia
hal.structure.identifierAP-HP Hôpital universitaire Robert-Debré [Paris]
dc.contributor.authorSIRIEZ, Jean-Yves
hal.structure.identifierGlobal Health in the Global South [GHiGS]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMALVY, Denis
ORCID: 0000-0003-1948-9355
IDREF: 148480993
hal.structure.identifierInstitut de recherche en santé, environnement et travail [Irset]
dc.contributor.authorGANGNEUX, Jean-Pierre
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorDUVIGNAUD, Alexandre
hal.structure.identifierMaladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle [MIVEGEC]
dc.contributor.authorRAVEL, Christophe
hal.structure.identifierOptimisation thérapeutique en Neuropsychopharmacologie [OPTeN (UMR_S 1144 / U1144)]
hal.structure.identifierHôpital Necker - Enfants Malades [AP-HP]
dc.contributor.authorCISTERNINO, Salvatore
hal.structure.identifierInstitut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
dc.contributor.authorCAUMES, Eric
hal.structure.identifierFast-Track Drugs and Biologics
dc.contributor.authorRANSOM, Janet
hal.structure.identifierHôpital Necker - Enfants Malades [AP-HP]
hal.structure.identifierCentre d'infectiologie Necker-Pasteur [CHU Necker]
hal.structure.identifierImagine - Institut des maladies génétiques (IHU) [Imagine - U1163]
dc.contributor.authorLORTHOLARY, Olivier
hal.structure.identifierCentro de Investigación Biomédica en Red de Enfermedades Infecciosas [CIBERINFEC]
hal.structure.identifierHospital Universitario 12 de Octubre [Madrid]
dc.contributor.authorGROGL, Max
hal.structure.identifierCentre d'infectiologie Necker-Pasteur [CHU Necker]
dc.contributor.authorBUFFET, Pierre
dc.date.accessioned2024-10-30T14:05:20Z
dc.date.available2024-10-30T14:05:20Z
dc.date.issued2023-08-10
dc.identifier.issn1935-2727en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/202997
dc.description.abstractEnBackground: In endemic foci, the use of an aquaphilic cream containing paromomycin with/without gentamicin to treat cutaneous leishmaniasis (CL) is safe, painless and cures 78-82% of patients with New and Old World CL. Self-application in travelers requires evaluation.Methods: Travelers with 1-10 lesions of confirmed CL were prospectively treated with the paromomycin-gentamicin formulation (WR279396, 2012-2017, Group 1) and carefully follow up, or treated with a locally produced paromomycin-only cream (2018-2022, Group 2). The cream was applied once under supervision, then self-applied daily for 20-30 days. A cured lesion was defined as 100% re-epithelialization at day 42 without relapse at three months. Results: Medical features were similar in Group 1 (17 patients), and Group 2 (23 patients). Patients were infected with either Leishmania major, L. infantum, L. killicki, L. guyanensis, L. braziliensis, or L. naiffi. Intention-to-treat and per-protocol cure rates were 82% (95% confidence interval (CI) [64.23;100.00]) and 87% (95% CI [71,29;100.00]) in Group 1, and 69% (95% CI [50.76; 88.37]) and 76% (95% CI [57.97; 94.41]) in Group 2. In the pooled Group 1 and 2, 75% (95% CI [61.58;88.42]) (30/40) and 81% (95% CI [68,46;93.6]) (30/37) of patients were cured in intention-to-treat and per-protocol, respectively. There were no significant differences observed in the success rates between Old World and New World CL (83.3% vs. 60%, p = 0.14). Prospective observations in Group 1 showed that adverse events were mainly pruritus (24%) and pain (18%) on lesions (all mild or moderate). No mucosal involvement was observed in either group.Discussion: In this representative population of travelers who acquired CL either in the Old or New World, the 81% per-protocol cure rate of a self-applied aminoglycoside cream was similar to that observed in clinical trials.
dc.language.isoENen_US
dc.rights.urihttp://creativecommons.org/licenses/by/
dc.title.enSelf-application of aminoglycoside-based creams to treat cutaneous leishmaniasis in travelers
dc.title.alternativePLoS Negl Trop Disen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1371/journal.pntd.0011492en_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologie/Maladies infectieusesen_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologie/Dermatologieen_US
dc.subject.halSciences du Vivant [q-bio]/Sciences pharmaceutiques/Pharmacologieen_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed37561802en_US
bordeaux.journalPLoS Neglected Tropical Diseasesen_US
bordeaux.pagee0011492en_US
bordeaux.volume17en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue8en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamGHIGS_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDInstitut de Recherche pour le Développementen_US
bordeaux.import.sourcehal
hal.identifierhal-04197812
hal.version1
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcehal
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=PLoS%20Neglected%20Tropical%20Diseases&rft.date=2023-08-10&rft.volume=17&rft.issue=8&rft.spage=e0011492&rft.epage=e0011492&rft.eissn=1935-2727&rft.issn=1935-2727&rft.au=MOURI,%20Oussama&MELENOTTE,%20Clea&GUERY,%20Romain&COTTERET,%20Camille&SCHWEITZER-CHAPUT,%20Arnaud&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_PosNTD_2023_Mouri.pdf
Taille:
1.238Mo
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée